MCID: LYM019
MIFTS: 46

Lymphosarcoma

Categories: Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Lymphosarcoma

MalaCards integrated aliases for Lymphosarcoma:

Name: Lymphosarcoma 20 54
Lymphoma, Diffuse 71
Lymphoma 71

Classifications:



External Ids:

UMLS 71 C0024299 C3714542

Summaries for Lymphosarcoma

MalaCards based summary : Lymphosarcoma, also known as lymphoma, diffuse, is related to reticulum cell sarcoma and lymphoma, non-hodgkin, familial. An important gene associated with Lymphosarcoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are Immune response Fc epsilon RI pathway and Chromatin Regulation / Acetylation. The drugs Ferrous succinate and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Reduced mammosphere formation and cellular

Wikipedia : 74 Lymphoma is a group of blood malignancies that develop from lymphocytes (a type of white blood cell).... more...

Related Diseases for Lymphosarcoma

Diseases related to Lymphosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 323)
# Related Disease Score Top Affiliating Genes
1 reticulum cell sarcoma 30.9 TNFRSF8 PTPRC
2 lymphoma, non-hodgkin, familial 29.9 TNFRSF8 PTPRC IGH CD22 BCL6 BCL2
3 follicular lymphoma 29.8 IGH BCL6 BCL2
4 alpha chain disease 29.8 CD22 BCL6
5 reticulosarcoma 29.5 TNFRSF8 PTPRC IGH BCL6 BCL2
6 lymphoblastic lymphoma 29.5 TNFRSF8 PTPRC BCL6
7 lymphoproliferative syndrome 29.2 TNFRSF8 PTPRC BCL6
8 leukemia, acute lymphoblastic 29.2 PTPRC NR3C1 IGH CD22 BCL6 BCL2
9 leukemia, chronic myeloid 29.1 PTPRC G6PD DNMT1 BCL2
10 hodgkin's lymphoma, lymphocytic-histiocytic predominance 29.1 TNFRSF8 PTPRC BCL6
11 diffuse large b-cell lymphoma 29.1 TNFRSF8 PTPRC BCL6 BCL2
12 burkitt lymphoma 29.0 TNFRSF8 DNMT1 BCL6 BCL2
13 leukemia, chronic lymphocytic 28.9 TNFRSF8 PTPRC IGH CD22 BCL6 BCL2
14 peripheral t-cell lymphoma 28.9 TNFRSF8 PTPRC DNMT3A BCL6
15 mantle cell lymphoma 28.8 PTPRC IGH BCL6 BCL2
16 t-cell lymphoblastic leukemia/lymphoma 28.6 TNFRSF8 PTPRC NR3C1 ERVW-1 BCL2
17 leukemia, acute myeloid 28.5 TNFRSF8 PTPRC DNMT3A DNMT1 CD22 BCL6
18 b-cell lymphoma 28.2 TNFRSF8 PTPRC IGH CD22 BCL6 BCL2
19 sarcoma 10.4
20 spindle cell sarcoma 10.4
21 acute leukemia 10.4
22 trimethoprim allergy 10.3 GSR G6PD
23 meningococcal infection 10.3 GSR G6PD
24 eye lymphoma 10.2 CD22 BCL6
25 leukemia 10.2
26 parotitis 10.2 H6PD G6PD
27 soft palate cancer 10.2 CD22 BCL6
28 epiglottis neoplasm 10.2 PTPRC BCL6
29 heart lymphoma 10.2 PTPRC BCL6
30 hemolytic anemia 10.1
31 glucosephosphate dehydrogenase deficiency 10.1 H6PD GSR G6PD
32 plasmablastic lymphoma 10.1 PTPRC BCL6
33 hypereosinophilic syndrome 10.1
34 posttransplant acute limbic encephalitis 10.1
35 nodal marginal zone b-cell lymphoma 10.1 BCL6 BCL2
36 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.1 BCL6 BCL2
37 intussusception 10.1
38 mycosis fungoides 10.1
39 peritonitis 10.1
40 splenomegaly 10.1
41 intravascular large b-cell lymphoma 10.1 BCL6 BCL2
42 ataxia and polyneuropathy, adult-onset 10.0
43 yemenite deaf-blind hypopigmentation syndrome 10.0
44 lymphoma 10.0
45 uveitis 10.0
46 lymphopenia 10.0
47 exophthalmos 10.0
48 spleen cancer 10.0 CD22 BCL6
49 neuropathy, hereditary sensory, type ie 10.0 DNMT3A DNMT1
50 testicular torsion 10.0 GSR BCL2

Graphical network of the top 20 diseases related to Lymphosarcoma:



Diseases related to Lymphosarcoma

Symptoms & Phenotypes for Lymphosarcoma

GenomeRNAi Phenotypes related to Lymphosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 BCL6 CD22 CTSL DNMT3A NR3C1 PTPRC

MGI Mouse Phenotypes related to Lymphosarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.81 BCL2 BCL6 CD22 DNMT1 DNMT3A G6PD
2 endocrine/exocrine gland MP:0005379 9.56 BCL2 BCL6 DNMT3A H6PD NR3C1 PTPRC
3 hematopoietic system MP:0005397 9.32 BCL2 BCL6 CD22 DNMT1 DNMT3A G6PD

Drugs & Therapeutics for Lymphosarcoma

Drugs for Lymphosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 803)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ferrous succinate Approved Phase 4 10030-90-7
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Palonosetron Approved, Investigational Phase 4 135729-56-5, 119904-90-4 148211
4
Teniposide Approved Phase 4 29767-20-2 34698
5
Nitric Oxide Approved Phase 4 10102-43-9 145068
6
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
7
Infliximab Approved Phase 4 170277-31-3
8
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
9
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
10
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
11
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
12
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
13
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
14
Prilocaine Approved Phase 4 721-50-6 4906
15
tannic acid Approved Phase 4 1401-55-4
16
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
17
Epirubicin Approved Phase 4 56420-45-2 41867
18
Blinatumomab Approved, Investigational Phase 4 853426-35-4
19
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
20
Zidovudine Approved Phase 4 30516-87-1 35370
21
Methoxsalen Approved Phase 4 298-81-7 4114
22
Ledipasvir Approved Phase 4 1256388-51-8 67505836
23
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
24
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
25
Ribavirin Approved Phase 4 36791-04-5 37542
26
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
27
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
28
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
29
Fotemustine Investigational Phase 4 92118-27-9
30 Clorazepate Dipotassium Phase 4
31
Ethylene Phase 4 74-85-1 6325
32 Serotonin 5-HT3 Receptor Antagonists Phase 4
33 Analgesics, Non-Narcotic Phase 4
34 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
35 Anesthetics Phase 4
36 Ionophores Phase 4
37 Calcium Ionophores Phase 4
38 Anesthetics, General Phase 4
39 Iron Supplement Phase 4
40 Ketorolac Tromethamine Phase 4
41 Anesthetics, Dissociative Phase 4
42 Excitatory Amino Acid Antagonists Phase 4
43 Anesthetics, Inhalation Phase 4
44 Vitamin D2 Phase 4
45 Ergocalciferols Phase 4
46 Hydroxycholecalciferols Phase 4
47 Anesthetics, Local Phase 4
48 Sodium Channel Blockers Phase 4
49 Anti-Arrhythmia Agents Phase 4
50 Diuretics, Potassium Sparing Phase 4

Interventional clinical trials:

(show top 50) (show all 6631)
# Name Status NCT ID Phase Drugs
1 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
2 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
3 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
4 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Unknown status NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
5 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Unknown status NCT03579082 Phase 4 Decitabine
6 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Unknown status NCT03558412 Phase 4 Decitabine
7 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
8 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Unknown status NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
9 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
10 A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy Unknown status NCT03150602 Phase 4 Pralatrexate
11 A Randomized Controlled Clinical Trial of Apatinib Combined With CHOP Regimen in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma Unknown status NCT03631862 Phase 4 Apatinib;CHOP Regimen
12 Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas Unknown status NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
13 Single-arm, Multi-center Clinical Study of Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory Anaplastic Lymphoma Kinase (ALK)-Positive Anaplastic Large Cell Lymphoma (ALCL) Unknown status NCT03707847 Phase 4 Crizotinib;Etoposide Capsule
14 EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial Unknown status NCT02858804 Phase 4 Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
15 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE (MTX,DEX,IFO,L-ASP,Etoposide,Mesna)
16 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage I/II NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501136 Phase 4
17 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
18 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
19 The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma. Unknown status NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
20 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
21 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
22 A Single Center Randomized Controlled Trial of the Efficacy and Safety of PEG-rhG-CSF After Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Patients Unknown status NCT02905942 Phase 4 PEG-rhG-CSF;rhG-CSF
23 Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
24 Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors Unknown status NCT02929615 Phase 4
25 German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
26 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
27 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
28 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
29 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
30 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
31 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
32 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
33 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Unknown status NCT02933333 Phase 4
34 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
35 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
36 AMENO-2: Fase IV Study, National, Multiple Centers, Competitive, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Security, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors Completed NCT00415103 Phase 4 Aprepitant;Palonosetron;Granisetron
37 Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
38 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
39 Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study Completed NCT03376958 Phase 4 Apatinib
40 Assisted Oocyte Activation (AOA) in Recurrent Fertilization Failure Completed NCT04744753 Phase 4 Calcium Ionophore A23187
41 A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
42 LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
43 UVADEX Sterile Solution in Conjunction With the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment Of CTCL (Mycosis Fungoides) in Patients With TMN Classification Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
44 A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25 Completed NCT00051012 Phase 4 ONTAK
45 A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25 Completed NCT00050999 Phase 4 ONTAK
46 Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
47 A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide ) Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
48 Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma Completed NCT01007448 Phase 4 Bexarotene
49 Estimation of Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene Treatment of Cutaneous T Cell Lymphoma - Pilote Study Completed NCT01569724 Phase 4
50 Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine

Search NIH Clinical Center for Lymphosarcoma

Inferred drug relations via UMLS 71 / NDF-RT 51 :


ASPARAGINASE
Cytarabine
Cytarabine liposome
irinotecan
Irinotecan hydrochloride
Mitoxantrone
Mitoxantrone Hydrochloride
Thiotepa

Genetic Tests for Lymphosarcoma

Anatomical Context for Lymphosarcoma

MalaCards organs/tissues related to Lymphosarcoma:

40
T Cells, Bone, Bone Marrow, Skin, Myeloid, Small Intestine, Liver

Publications for Lymphosarcoma

Articles related to Lymphosarcoma:

(show top 50) (show all 4267)
# Title Authors PMID Year
1
Suppression of metallothionein-I/II expression and its probable molecular mechanisms. 54 61
12426140 2002
2
[Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas]. 54 61
11494447 2001
3
Proteomic profiling of milk small extracellular vesicles from bovine leukemia virus-infected cattle. 61
33536533 2021
4
Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features. 61
33528622 2021
5
Analysis of preventability of malignancy-related maternal death from the nationwide registration system of maternal deaths in Japan. 61
30999803 2021
6
PTEN Loss and Cyclin A2 Upregulation Define a PI3K/AKT Pathway Activation in Helicobacter pylori-induced MALT and DLBCL Gastric Lymphoma With Features of MALT. 61
32134755 2021
7
Prognostic role of regulatory T cells in lymphoma: a systematic review and meta-analysis. 61
32995955 2020
8
Hematolymphoid Neoplasms Rarely Mimic Undifferentiated Pleomorphic Sarcoma of Soft Tissue. 61
32167380 2020
9
Data on proteomic analysis of milk extracellular vesicles from bovine leukemia virus-infected cattle. 61
33294510 2020
10
Antitumour Activity of the Ribonuclease Binase from Bacillus pumilus in the RLS40 Tumour Model Is Associated with the Reorganisation of the miRNA Network and Reversion of Cancer-Related Cascades to Normal Functioning. 61
33147876 2020
11
EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas. 61
31789821 2020
12
Kappa and lambda immunohistochemistry and in situ hybridization in the evaluation of atypical cutaneous lymphoid infiltrates. 61
32870521 2020
13
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. 61
32888407 2020
14
CpG Site-Specific Regulation of Metallothionein-1 Gene Expression. 61
32824906 2020
15
Impact of bovine leukemia virus infection on beef cow longevity. 61
32593082 2020
16
Phylogenetic Analysis of South African Bovine Leukaemia Virus (BLV) Isolates. 61
32824449 2020
17
Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma. 61
32755987 2020
18
Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG. 61
32757068 2020
19
Vitamin D levels in patients with non-Hodgkin lymphoma/diffuse large B-cell lymphoma, chronic lymphocytic leukemia and multiple myeloma. 61
32722995 2020
20
Re-defining Prognosis of Hematological Malignancies by Dynamic Response Assessment Methods: Lessons Learnt in Chronic Myeloid Leukemia, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma and Multiple Myeloma. 61
32647417 2020
21
Diffuse large B cell lymphoma in a preceding IgG4-related disease with kidney restricted lambda light chain expression: case report and literature review. 61
32727411 2020
22
[Application of Antinuclear Antibody and Antinuclear Antibody Spectrum in Lymphoma Treatment]. 61
32552948 2020
23
Targeting Circulating SINEs and LINEs with DNase I Provides Metastases Inhibition in Experimental Tumor Models. 61
32146418 2020
24
Population-based study of patients with primary Sjögren's syndrome and lymphoma: lymphoma subtypes, clinical characteristics, and gender differences. 61
32153241 2020
25
Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. 61
32135128 2020
26
Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases. 61
32030731 2020
27
Update on the subcutaneous administration of rituximab in Canadian cancer centres. 61
32489254 2020
28
To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma). 61
32073552 2020
29
An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy. 61
32228625 2020
30
Rare case of Richter's syndrome localization in liver and thyroid of a patient with a chronic lymphocytic leukemia (CLL) - Case report and literature. 61
32208597 2020
31
Approbation of the Cancer Treatment Approach Based on the Eradication of TAMRA+ Cancer Stem Cells in a Model of Murine Cyclophosphamide Resistant Lymphosarcoma. 61
32014922 2020
32
Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact. 61
32457824 2020
33
Whole genome sequencing analysis of high confidence variants of B-cell lymphoma in Canis familiaris. 61
32857815 2020
34
Foliate Lymphoid Aggregates as Novel Forms of Serous Lymphocyte Entry Sites of Peritoneal B Cells and High-Grade B Cell Lymphomas. 61
31767783 2020
35
Primary pulmonary lymphoma manifesting as diffuse ground glass opacities: a case report and literature review. 61
32922618 2020
36
Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use. 61
31648953 2019
37
Interferon gamma inducible protein 16 (IFI16) expression is reduced in mantle cell lymphoma. 61
31840115 2019
38
Cancer Incidence and Mortality in Firefighters: A State-of-the-Art Review and Meta-َAnalysis. 61
31759344 2019
39
Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives. 61
30993718 2019
40
Detection and Identification of Enzootic Bovine Leukosis (EBL) in Calves in Iran. 61
31592598 2019
41
Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook. 61
30045683 2019
42
Prevalence and clinical significance of koala retrovirus in two South Australian koala (Phascolarctos cinereus) populations. 61
31162024 2019
43
The Unsolved Puzzle of c-Rel in B Cell Lymphoma. 61
31277480 2019
44
Surveillance scanning in lymphoma. 61
31437139 2019
45
Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. 61
30795996 2019
46
A phase III randomized controlled trial of radiation dose optimization in non-Hodgkin lymphoma-diffuse large B-cell lymphoma (DOBL study): Study protocol and design. 61
32935480 2019
47
Incidence of Neoplasia in Pigs and Its Relevance to Clinical Organ Xenotransplantation. 61
30909988 2019
48
Will donor-derived neoplasia be problematic after clinical pig organ or cell xenotransplantation? 61
30411396 2019
49
Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma). 61
29419530 2019
50
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. 61
30642819 2019

Variations for Lymphosarcoma

Expression for Lymphosarcoma

Search GEO for disease gene expression data for Lymphosarcoma.

Pathways for Lymphosarcoma

Pathways related to Lymphosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.99 PTPRC IGH CD22 BCL6
2 11.66 SMARCA4 NR3C1 DNMT3A DNMT1
3 11.62 SMARCA4 BCL6 BCL2
4 10.51 GSR G6PD
5 10.27 SMARCA4 DNMT3A DNMT1 BCL2

GO Terms for Lymphosarcoma

Cellular components related to Lymphosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replication fork GO:0005657 8.62 DNMT1 BCL6

Biological processes related to Lymphosarcoma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.92 SMARCA4 NR3C1 DNMT3A DNMT1 BCL6
2 regulation of gene expression GO:0010468 9.78 PTPRC DNMT3A DNMT1 BCL2
3 chromatin organization GO:0006325 9.76 SMARCA4 NR3C1 DNMT3A DNMT1
4 negative regulation of cell growth GO:0030308 9.67 SMARCA4 BCL6 BCL2
5 response to gamma radiation GO:0010332 9.55 PTPRC BCL2
6 DNA methylation GO:0006306 9.54 DNMT3A DNMT1
7 B cell differentiation GO:0030183 9.54 PTPRC BCL6 BCL2
8 negative regulation of reactive oxygen species metabolic process GO:2000378 9.51 G6PD BCL2
9 pentose-phosphate shunt GO:0006098 9.43 H6PD G6PD
10 NADP metabolic process GO:0006739 9.4 H6PD G6PD
11 DNA methylation involved in embryo development GO:0043045 9.32 DNMT3A DNMT1
12 C-5 methylation of cytosine GO:0090116 9.26 DNMT3A DNMT1
13 pentose-phosphate shunt, oxidative branch GO:0009051 9.16 H6PD G6PD
14 positive regulation of B cell proliferation GO:0030890 9.13 PTPRC BCL6 BCL2
15 DNA methylation on cytosine GO:0032776 8.62 DNMT3A DNMT1

Molecular functions related to Lymphosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 NADP binding GO:0050661 9.33 H6PD GSR G6PD
2 oxidoreductase activity, acting on CH-OH group of donors GO:0016614 9.32 H6PD G6PD
3 DNA-methyltransferase activity GO:0009008 9.26 DNMT3A DNMT1
4 DNA (cytosine-5-)-methyltransferase activity GO:0003886 8.96 DNMT3A DNMT1
5 glucose-6-phosphate dehydrogenase activity GO:0004345 8.62 H6PD G6PD

Sources for Lymphosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....